Teaneck-based Phibro Animal Health Corp. is creating a biotech facility in Ireland, it announced Thursday.
The New Jersey maker of animal health and nutrition products said the facility in the IDA Ireland Finisklin Business Park in Sligo will produce animal health vaccines. The company will create up to 150 jobs at the facility over the next five years, it added.
The project received support from the Irish government through IDA Ireland, the country’s development agency. This will be its first biologicals manufacturing site in Europe; it will initially work on poultry disease vaccines, eventually expanding to livestock and aquaculture vaccines.
“The creation of Phibro Ireland marks an important milestone in our development as a leading global player in the animal health biological market,” Jack Bendheim, Phibro’s chairman, CEO and president, said in a prepared statement. “The winning combination of Phibro’s expertise in the development and manufacuture of biological products, the driven and experienced workforce available in the Sligo area and the strong support of the IDA makes us very excited about the potential of the Sligo facility.”
Although no financial costs of the project were announced, Phibro said it anticipates products could contribute to the company’s financial results within three to five years.
